Results 141 to 150 of about 679,289 (268)

Optimizing Growth Regulator Concentrations for <i>Cannabis sativa</i> L. Micropropagation. [PDF]

Plants (Basel)
Johnson GA, Jackson CL, Timoteo A, Sardaru P, Foland MH, Natarajan P, Dhekney SA.   +6 more
europepmc   +1 more source

Plant Growth Regulator- and Elicitor-Mediated Enhancement of Biomass and Andrographolide Production of Shoot Tip-Culture-Derived Plantlets of Andrographis paniculata (Burm.f.) Wall. (Hempedu Bumi). [PDF]

Plants (Basel), 2023
Patuhai A, Wahab PEM, Yusoff MM, Dewir YH, Alsughayyir A, Hakiman M.   +5 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Sublethal Effects of the Insect Growth Regulator Novaluron on the Midgut Integrity and Survival of Adult Honey Bee <i>Apis mellifera</i> Workers. [PDF]

ACS Environ Au
Soares de Oliveira M, Motta JVO, Gomes DS, Pereira GDS, Pantoja GM, da Silva LL, Cruz JPPO, Serrão JE.   +7 more
europepmc   +1 more source

Susceptibility status of major malaria vectors to novaluron, an insect growth regulator South-Eastern Tanzania. [PDF]

Pan Afr Med J, 2022
Ngonzi AJ, Muyaga LL, Ngowo H, Urio N, Vianney JM, Lwetoijera DW.   +5 more
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Correction: Growth, leaf anatomy, and photosynthesis of cotton (Gossypium hirsutum L.) seedlings in response to four light-emitting diodes and high pressure sodium lamp

Journal of Cotton Research
Yichi Zhang, Baopeng Liao, Fangjun Li, A. Egrinya Eneji, Mingwei Du, Xiaoli Tian   +5 more
doaj   +1 more source

Sex-specific difference on anxiety- and depressive-like behavior in neuronal growth regulator 1-knockout mice. [PDF]

Biol Sex Differ
Lee SR, Yoon E, Baek S, Kim JG, Kim JO, Yoon SI, Lee S, Cho JA.   +7 more
europepmc   +1 more source

Neuronal growth regulator 1 promotes adipocyte lipid trafficking via interaction with CD36. [PDF]

J Lipid Res, 2022
Yoo A, Joo Y, Cheon Y, Lee SJ, Lee S.
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source